Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes
Jessica L Fairley, Dylan Hansen, Susanna Proudman, Joanne Sahhar, Gene-Siew Ngian, Jenny Walker, Gemma Strickland, Michelle Wilson, Kathleen Morrisroe, Nava Ferdowsi, Gabor Major, Janet Roddy, Wendy Stevens, Mandana Nikpour
ARTHRITIS CARE & RESEARCH | WILEY | Published : 2021
OBJECTIVE: To describe the clinical characteristics and outcomes of systemic sclerosis-mixed connective tissue disease (SSc-MCTD) and SSc overlap syndrome. METHODS: We included patients from the Australian Scleroderma Cohort Study who met American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for SSc. Three mutually exclusive groups were created: SSc-MCTD, SSc overlap, and SSc only. Univariate comparison of clinical features was performed by analysis of variance or chi-square test. Survival analysis was performed using Kaplan-Meier (KM) curves and Cox proportional hazards regression models. RESULTS: Of 1,728 patients, 97 (5.6%) had SSc-MCTD, and 126 (7.3..View full abstract
Awarded by National Health and Medical Research Council
Dr. Morrisroe's work was supported by an Arthritis Australia Fellowship. Dr. Nikpour is recipient of a National Health and Medical Research Council Career Development Fellowship (grant APP1126370).The Australian Scleroderma Cohort Study is supported by Actelion, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, the Australian Rheumatology Association, the St. Vincent's Hospital Melbourne Research Endowment Fund, GlaxoSmithKline, Pfizer, Bristol Myers Squibb, Roche, and Bayer. The Australian Scleroderma Interest Group is supported by Actelion.